MedTrace Logo

Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C

NCT00209755 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2005-09-21

No results posted yet for this study

Summary

Investigation of the usefullness of therapeutical drug monitoring of ribavirin for dose adaptation during combination therapy of chronic hepatitis C patients.

The correlation between ribavirin plasma concentration levels at week 4 (steady state) and early virological response (HCV-RNA decay from baseline to week 12) is to be tested in 40 patients approximately.

Conditions

  • Chronic Hepatitis C

Interventions

PROCEDURE

therapeutic drug monitoring of ribavirin and dose adaptation

Sponsors & Collaborators

  • University Hospital, Grenoble

    collaborator OTHER

  • Central Hospital, Nancy, France

    collaborator OTHER

  • Hopital A Michallon

    lead OTHER

Principal Investigators

  • Jean Pierre ZARSKI, MD · university hospital of Grenoble (France)

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2004-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209755 on ClinicalTrials.gov